Management

FH.png
DPt8LeTWkAAmqF2_burned.jpg
EC.png
NS.png

Fabrice Harari

Chairman

Barak Palatchi

Chief Executive Officer

Emmanuel Coeytaux

Head of US Operations

Niso Sadik

Corporate Development

 

Advisors

AS.png
JPB.png
DT.png
MF.png

Avigdor Scherz

Scientific Advisor

Jean-Pierre Bizzari

Scientific Advisor

Daniel Teper

Strategic Advisor

Michael Friedman

Strategic Advisor

 

About Steba Biotech

Steba Biotech is a privately owned biotechnology company dedicated to the development and commercialization of novel therapies for cancer that enable targeted and effective tumor ablation while sparing healthy organ. Headquartered in Luxembourg with offices in France, Israel, Switzerland and the U.S., Steba has developed TOOKAD® (padeliporfin di-potassium), an innovative and minimally invasive photodynamic therapy, which is approved for the treatment of early stage prostate cancer in Europe, Israel, and Mexico. Steba also develops its therapeutic platform, in collaboration with leading academic institution such as the Weizmann Institute, Memorial Sloan Kettering Cancer Center, and Oxford University, to treat urothelial carcinoma, esophageal cancer, lung cancer, and  pancreatic cancer.  

Steba Biotech partners with the best scientists and clinicians to advance disruptive technologies that translate in cost effective clinical solutions for cancer patients.

Our vision is to revolutionize cancer care by preventing or delaying radical therapy (surgery or radiotherapy), enabling patients with localized tumors to maintain their quality of life for many years.

c26_ha800-1.jpg

Our Story

Steba Biotech is a privately-owned biotechnology company focused on the development of innovative and minimally invasive light-activated therapies and systems to treat cancers.

Spun out in 1996 from the Weizmann Institute in Rehovot, Israel, we are now a global company with presence in Israel, Europe, and the US. We maintain close research partnerships with both the Weizmann Institute and the Memorial Sloan Kettering Cancer Center, supported by a grant from the Thompson Family Foundation.

Vascular Targeted Photodynamic Therapy for Prostate Tumors

Prostate Cancer Laser Treatment "Truly Transformative" 

Killing early-stage prostate cancer tumours in 90 minutes

Management

DPt8LeTWkAAmqF2_burned.jpg
Steba Bio 2.jpg
Smiling Man with Glasses
Happy Young Man

Barak Palatchi

Chief Executive Officer

Chris Grimes

Chief Commercial Officer

Team Member

Chief Marketing Officer

Team Member

Head of Production

Young Woman with Curly Hair

Team Member

Investor Relations

 

News & Events

Steba Biotech Wins Top Industry Award

March 1, 2025

Offsite Takeaways: Doing it the Steba Biotech Way

March 1, 2025

New Startup Changing The Game

March 1, 2025

Gregory's Story

By Jennifer Castoro

New York City dentist Gregory Page had seen several friends suffer troubling side effects after surgery for prostate cancer. When he was diagnosed with the disease himself, he sought out a less-invasive option. He found it with MSK surgeon Jonathan Coleman, who performs a procedure called vascular-targeted photodynamic therapy. Gregory quickly returned to life as normal.

greg-1200x800.jpg

A Patient-Focused Revolution in Oncology

 

A Patient-Focused Revolution in Oncology

 

Investors & Media

News & Events

Presentations

Media

 A PLATFORM FOR SELECTIVE CANCER TREATMENT

 An intravenously-administered drug activated by a low-energy, non-thermal laser light.

Scientific Publications

Scientific Publications

About Vascular Photodynamic Therapy/Our Product

Vascular Photodynamic Therapy/Our Product is a novel, minimally invasive, and targeted treatment option, which is approved in Europe and Israel for the treatment of patients with early stage prostate cancer and under investigation for other localized tumors (urothelial, esophageal, lung, pancreatic). It is a drug-device combination that features a light activated drug and a light delivery system. The drug is administered intravenously and is activated locally  with light fibers that deliver low-energy, non-thermal laser light with millimeter accuracy. Upon activation, VTP/The Product rapidly triggers the constriction of the blood supply in the illuminated area only, resulting in targeted tumor necrosis.

About Steba Biotech

Steba Biotech is a Luxembourg based biotech company which holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize Vascular Targeted Photodynamic Therapy (VTP) and related technologies.

VTP/Our Product is a potential mainstay cancer therapy that offers a novel platform for the unmet need of organ preserving treatment of solid tumors at the localized and metastatic stage.


VTP/Our Product's innovative approach comprises intravenous delivery of non-toxic drug fibers. Its activation in the tumor circulation results in immediate occlusion of the tumor blood supply followed by self-propagating necrosis of the entire tumor with minimal collateral damage to surrounding normal tissue. The necrotic cell death triggers antitumor immunity that can be amplified by combining  VTP/Our Product with various drugs including checkpoint inhibitors, resulting in regression of remote metastases.

A Novel Treatment Path

Steba focuses on the development of minimally-invasive treatments that rely on a drug requiring the action of light to become active (photodynamic therapy). Utilizing a low-energy, non-thermal laser light channeled through optical fibers, this treatment provides a new approach to localized tumors, with potential for treating various sites in the body.


By treating solid tumors locally, we are limiting the need for radical treatments such as surgery and radiotherapy, minimizing the risk of side effects, optimizing quality of life, and protecting the tissues and organs affected by cancer. 


After an initial focus on prostate cancer, our partnership with the Memorial Sloan Kettering Cancer Center has allowed us to uncover multiple additional indications the focal therapy technology can be applied to

fibres 2.jpg

A Novel Treatment Path

Steba’s technology consists of a minimally-invasive treatment that combines a photosensitive drug with activation by a non-thermal light delivery system. Utilizing a low-energy laser light channeled through optical fibers, this treatment provides a new approach to localized tumors, with the potential to treat various sites in the body.


This therapeutic approach enables targeted ablation of solid tumors locally and minimizes the risk of side effects by preserving the surrounding healthy tissues and organs. It thereby enables treatment of sometimes inoperable tumors and optimizes quality of life of patients.


After an initial focus on prostate cancer, our partnership with the Weizmann Institute and the Memorial Sloan Kettering Cancer Center has allowed us to explore multiple additional indications our technology can be applied to.

fibres-et-bactГ©riochlorophylle-1-partie

Our Research & Development Pipeline

©2020 by Steba Biotech. Proudly created with Wix.com

Steba biotech ©